Where does Genentech, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Genentech, Inc. ranks #437 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Genentech, Inc. hold?

Genentech, Inc. holds 1,039 US utility patents granted between 2015 and 2025, spanning 46 technology areas.

What is Genentech, Inc.'s Innovation Score?

Genentech, Inc. has an Innovation Score of 66.6 out of 100 (top 1% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Genentech, Inc.'s patent grant rate increasing or decreasing?

Genentech, Inc.'s recent grant velocity is -12% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Genentech, Inc.'s patents?

Genentech, Inc.'s patents average 23.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Genentech, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Genentech, Inc.

Q: What technology areas does Genentech, Inc. focus on?

Genentech, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 789 patents. Grants appear in 46 CPC subclasses total.

USPTO PatentsView assignee record - 1,039 granted patents across 46 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Genentech ranks #437 of 49,997 tracked US assignees by granted-patent volume, with 1,039 patents across 46 technology areas.

#437
of 49,997 US assignees by volume: Top 1%
by Innovation Score (66.6/100): 23.2
avg claims per patent: -12%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R437 · US Corporation #437 · 1,039 grants

GRANTS-LARGE · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-LARGE 1.0K grants
TOP-DECILE #437/49,997
PHOTO-FINISH Mitsubishi Chemical
CPC-WIDE A61P · 46 areas
INNOV-STRONG 66.6/100
CLAIMS-DENSE 23.2 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -12% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Mitsubishi Chemical Corporation (±1 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Genentech · this assignee

67
Renesas America · near

67
Lumentum Operations · near

67
TDK · near

67
The General Hospital · near

67
3D Lighting… · lowest

7

What this shows Genentech's Innovation Score is 66.6/100 (top 1% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Genentech's grants concentrate

Genentech, Inc. is a focused PatentsView assignee: 46 CPC subclasses with 75.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (129 grants) versus a trough of 66 in 2022. By volume, Genentech sits between Largan Precision Co., Ltd. and Carl Zeiss SMT GmbH.

Genentech's three-year grant acceleration

From 2019–2021 to 2022–2024, Genentech, Inc. moved from 322 to 229 grants (0.71x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,115. See the growth leaderboard.

Largan Precision

1,046
Avaya

1,044
Toyota Jidoshokki

1,041
Mitsubishi Chemic…

1,040
Genentech ◀

1,039
Seoul National Un…

1,030
Align Technology

1,029
Contemporary Ampe…

1,029
Carl Zeiss SMT

1,028

What this shows Genentech holds 1,039 patents at rank #437, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Genentech

By rank, the assignees closest to #437 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Genentech's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Genentech, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (67 here).

Renesas Electronics America Inc. 67 Lumentum Operations LLC 67 The General Hospital Corporation 67 TDK Corporation 67

Similar claim depth

Nearest assignees by average claims per patent (23.2 here).

Innova Electronics Corporation 23.2 avg Comcast Cable Communications Management, LLC 23.2 avg Beta Bionics, Inc. 23.1 avg Ingevity South Carolina, LLC 23.1 avg

Genentech's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

67 Top 1% higher than 99% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Genentech, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	82	7.9%
2016	93	9.0%
2017	104	10.0%
2018	129	12.4%
2019	102	9.8%
2020	113	10.9%
2021	107	10.3%
2022	66	6.4%
2023	77	7.4%
2024	86	8.3%
2025partial year	80	7.7%

Which technologies does Genentech, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 789

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 673

C07K - Peptides 565

C07D - Heterocyclic Compounds 334

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 201

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 100

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 70

Y02A - Technologies FOR Adaptation TO Climate Change 46

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 36

C07C - Acyclic OR Carbocyclic Compounds 34

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 31

C12Y - Enzymes 31

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 25

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 23

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 20

Top 15 of 46 technology areas

Where it ranks

Overall rank by patents

#437

of 49,997 tracked assignees

Innovation Score

66.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Genentech, Inc.'s patent record in context - here's where to go next.

Genentech, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 75.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #437 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Genentech, Inc. against Largan Precision Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 66.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.